A new study from the University of Birmingham has shown that Faecal Microbiota Transplants (FMT) are highly successful in treating patients with Clostridioides difficile (C.diff) infection. Published ...

The antibiotic vancomycin, recommended as first-line treatment for infection caused by the deadly superbug C. difficile (C. diff), may not be living up to its promise, according to new research. The ...

Clostridium difficile bacteria, computer illustration. C. difficile is a normal inhabitant of the human intestine, but it can become a pathogen when antibiotics disrupt the normal intestinal flora and ...

Christian John Lillis, cofounder and executive director of the Peggy Lillis Foundation for C difficile Education & Advocacy, explained how FDA-approved microbiome-based therapeutics help to treat and ...

C. diff (Clostridioides difficile) is bacteria that causes about 500,000 infections a year in the United States, according to the U.S. Centers for Disease Control and Prevention (CDC). It can have ...

Clostridioides difficile is an uncommon but quite serious cause of diarrhea, and it is often associated with antibiotics.

1. Fidaxomicin, a newer treatment for C. diff, was often the most cost-effective treatment, though the findings were not definitive, as results from the individual studies largely varied based on the ...

SIOUX FALLS, S.D., Aug. 09, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (SABS) (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces ...

MALIBU, Calif., Nov. 13, 2019 /PRNewswire/ -- Several doctors spoke before the FDA in Washington D.C. on November 4, advocating for C.diff treatment improvements. Among those in attendance were ...

Researchers from North Carolina State University have found that a commonly used drug made from secondary bile acids can affect the life cycle of Clostridioides difficile (C. diff) in vitro and reduce ...